Recognition of platinum-induced DNA damage by nuclear proteins: Screening for mechanisms

Brian Marples, H. Adomat, P. C. Billings, N. P. Farrell, C. J. Koch, K. A. Skov

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

The association of high mobility group (HMG) proteins with cisplatin-damaged DNA has attracted considerable interest because of a possible relationship with drug-acquired resistance and the repair of DNA damage caused by this important chemotherapeutic agent. We have further characterized the binding of HMG proteins to cisplatin-damaged DNA using a modification of the damaged DNA affinity precipitation assay (DDAP) and proteins isolated from the nuclei of V79 cells. HMG proteins recognized cisplatin adducts only in double-stranded DNA sequences. Pre-treatment of cells with cisplatin (1 μM) prior to protein extraction decreased the apparent yield of HMG proteins. However, the pre-treatment of isolated protein did not prevent recognition of the DNA adducts. To investigate the possible role of HMG proteins in toxicity and resistance, we have extended the DDAP method to study other platinum agents, some of which are active in cisplatin-resistant cells. A comparison of trans- and cis-[PtCl2(NH3)quinoline] is presented as an example. HMG proteins recognized DNA damage caused by the cis, but not the trans isomer. However, the trans isomer is known to be significantly more toxic and is highly active in cisplatin-resistant cells, suggesting a mechanism of action different from cisplatin. Therefore, the toxicity of trans-[PtCl2(NH3)quinoline] appears to be unrelated to the recognition of damage by HMG proteins. The DDAP assay may provide an additional screen for new mechanisms of cytotoxic platinum agents.

Original languageEnglish (US)
Pages (from-to)389-399
Number of pages11
JournalAnti-Cancer Drug Design
Volume9
Issue number5
StatePublished - Jan 1 1994
Externally publishedYes

Fingerprint

High Mobility Group Proteins
Nuclear Proteins
Platinum
Cisplatin
DNA Damage
Screening
DNA
Assays
Isomers
Toxicity
Proteins
DNA Adducts
Poisons
Cytotoxins
Cell Nucleus
DNA sequences
Drug Resistance
Repair
Cells
Association reactions

Keywords

  • Cisplatin
  • DNA-binding proteins
  • HMG proteins
  • Platinum adducts
  • Quinolines

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Biochemistry
  • Organic Chemistry
  • Oncology
  • Drug Discovery
  • Pharmacology

Cite this

Marples, B., Adomat, H., Billings, P. C., Farrell, N. P., Koch, C. J., & Skov, K. A. (1994). Recognition of platinum-induced DNA damage by nuclear proteins: Screening for mechanisms. Anti-Cancer Drug Design, 9(5), 389-399.

Recognition of platinum-induced DNA damage by nuclear proteins : Screening for mechanisms. / Marples, Brian; Adomat, H.; Billings, P. C.; Farrell, N. P.; Koch, C. J.; Skov, K. A.

In: Anti-Cancer Drug Design, Vol. 9, No. 5, 01.01.1994, p. 389-399.

Research output: Contribution to journalArticle

Marples, B, Adomat, H, Billings, PC, Farrell, NP, Koch, CJ & Skov, KA 1994, 'Recognition of platinum-induced DNA damage by nuclear proteins: Screening for mechanisms', Anti-Cancer Drug Design, vol. 9, no. 5, pp. 389-399.
Marples B, Adomat H, Billings PC, Farrell NP, Koch CJ, Skov KA. Recognition of platinum-induced DNA damage by nuclear proteins: Screening for mechanisms. Anti-Cancer Drug Design. 1994 Jan 1;9(5):389-399.
Marples, Brian ; Adomat, H. ; Billings, P. C. ; Farrell, N. P. ; Koch, C. J. ; Skov, K. A. / Recognition of platinum-induced DNA damage by nuclear proteins : Screening for mechanisms. In: Anti-Cancer Drug Design. 1994 ; Vol. 9, No. 5. pp. 389-399.
@article{1e60ffe7f1b44186a1803c102630325a,
title = "Recognition of platinum-induced DNA damage by nuclear proteins: Screening for mechanisms",
abstract = "The association of high mobility group (HMG) proteins with cisplatin-damaged DNA has attracted considerable interest because of a possible relationship with drug-acquired resistance and the repair of DNA damage caused by this important chemotherapeutic agent. We have further characterized the binding of HMG proteins to cisplatin-damaged DNA using a modification of the damaged DNA affinity precipitation assay (DDAP) and proteins isolated from the nuclei of V79 cells. HMG proteins recognized cisplatin adducts only in double-stranded DNA sequences. Pre-treatment of cells with cisplatin (1 μM) prior to protein extraction decreased the apparent yield of HMG proteins. However, the pre-treatment of isolated protein did not prevent recognition of the DNA adducts. To investigate the possible role of HMG proteins in toxicity and resistance, we have extended the DDAP method to study other platinum agents, some of which are active in cisplatin-resistant cells. A comparison of trans- and cis-[PtCl2(NH3)quinoline] is presented as an example. HMG proteins recognized DNA damage caused by the cis, but not the trans isomer. However, the trans isomer is known to be significantly more toxic and is highly active in cisplatin-resistant cells, suggesting a mechanism of action different from cisplatin. Therefore, the toxicity of trans-[PtCl2(NH3)quinoline] appears to be unrelated to the recognition of damage by HMG proteins. The DDAP assay may provide an additional screen for new mechanisms of cytotoxic platinum agents.",
keywords = "Cisplatin, DNA-binding proteins, HMG proteins, Platinum adducts, Quinolines",
author = "Brian Marples and H. Adomat and Billings, {P. C.} and Farrell, {N. P.} and Koch, {C. J.} and Skov, {K. A.}",
year = "1994",
month = "1",
day = "1",
language = "English (US)",
volume = "9",
pages = "389--399",
journal = "Anti-Cancer Drug Design",
issn = "0266-9536",
publisher = "Cognizant Communication Corporation",
number = "5",

}

TY - JOUR

T1 - Recognition of platinum-induced DNA damage by nuclear proteins

T2 - Screening for mechanisms

AU - Marples, Brian

AU - Adomat, H.

AU - Billings, P. C.

AU - Farrell, N. P.

AU - Koch, C. J.

AU - Skov, K. A.

PY - 1994/1/1

Y1 - 1994/1/1

N2 - The association of high mobility group (HMG) proteins with cisplatin-damaged DNA has attracted considerable interest because of a possible relationship with drug-acquired resistance and the repair of DNA damage caused by this important chemotherapeutic agent. We have further characterized the binding of HMG proteins to cisplatin-damaged DNA using a modification of the damaged DNA affinity precipitation assay (DDAP) and proteins isolated from the nuclei of V79 cells. HMG proteins recognized cisplatin adducts only in double-stranded DNA sequences. Pre-treatment of cells with cisplatin (1 μM) prior to protein extraction decreased the apparent yield of HMG proteins. However, the pre-treatment of isolated protein did not prevent recognition of the DNA adducts. To investigate the possible role of HMG proteins in toxicity and resistance, we have extended the DDAP method to study other platinum agents, some of which are active in cisplatin-resistant cells. A comparison of trans- and cis-[PtCl2(NH3)quinoline] is presented as an example. HMG proteins recognized DNA damage caused by the cis, but not the trans isomer. However, the trans isomer is known to be significantly more toxic and is highly active in cisplatin-resistant cells, suggesting a mechanism of action different from cisplatin. Therefore, the toxicity of trans-[PtCl2(NH3)quinoline] appears to be unrelated to the recognition of damage by HMG proteins. The DDAP assay may provide an additional screen for new mechanisms of cytotoxic platinum agents.

AB - The association of high mobility group (HMG) proteins with cisplatin-damaged DNA has attracted considerable interest because of a possible relationship with drug-acquired resistance and the repair of DNA damage caused by this important chemotherapeutic agent. We have further characterized the binding of HMG proteins to cisplatin-damaged DNA using a modification of the damaged DNA affinity precipitation assay (DDAP) and proteins isolated from the nuclei of V79 cells. HMG proteins recognized cisplatin adducts only in double-stranded DNA sequences. Pre-treatment of cells with cisplatin (1 μM) prior to protein extraction decreased the apparent yield of HMG proteins. However, the pre-treatment of isolated protein did not prevent recognition of the DNA adducts. To investigate the possible role of HMG proteins in toxicity and resistance, we have extended the DDAP method to study other platinum agents, some of which are active in cisplatin-resistant cells. A comparison of trans- and cis-[PtCl2(NH3)quinoline] is presented as an example. HMG proteins recognized DNA damage caused by the cis, but not the trans isomer. However, the trans isomer is known to be significantly more toxic and is highly active in cisplatin-resistant cells, suggesting a mechanism of action different from cisplatin. Therefore, the toxicity of trans-[PtCl2(NH3)quinoline] appears to be unrelated to the recognition of damage by HMG proteins. The DDAP assay may provide an additional screen for new mechanisms of cytotoxic platinum agents.

KW - Cisplatin

KW - DNA-binding proteins

KW - HMG proteins

KW - Platinum adducts

KW - Quinolines

UR - http://www.scopus.com/inward/record.url?scp=0028051759&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028051759&partnerID=8YFLogxK

M3 - Article

C2 - 7945723

AN - SCOPUS:0028051759

VL - 9

SP - 389

EP - 399

JO - Anti-Cancer Drug Design

JF - Anti-Cancer Drug Design

SN - 0266-9536

IS - 5

ER -